Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015;88(1056):20150453.
doi: 10.1259/bjr.20150453. Epub 2015 Oct 22.

Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom

Yat Tsang  1   2 , Laura Ciurlionis  1   2 , Anna M Kirby  3 , Imogen Locke  3 , Karen Venables  1   2 , John R Yarnold  4 , Jenny Titley  4 , Judith Bliss  4 , Charlotte E Coles  5 ; IMPORT Trial Management Group
Collaborators, Affiliations
Randomized Controlled Trial

Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom

Yat Tsang et al. Br J Radiol. 2015.

Abstract

Objective: IMPORT HIGH is a multicentre randomized UK trial testing dose-escalated intensity-modulated radiotherapy (IMRT) after tumour excision in females with early breast cancer and higher than average local recurrence risk. A survey was carried out to investigate the impact of this trial on the adoption of advanced breast radiotherapy (RT) techniques in the UK.

Methods: A questionnaire was sent to all 26 IMPORT HIGH recruiting RT centres to determine whether the trial has influenced non-trial breast RT techniques in terms of volume delineation, dosimetry, treatment delivery and verification. In order to compare the clinical practice of breast RT between IMPORT HIGH and non-IMPORT HIGH centres, parts of the Royal College of Radiologists (RCR) breast RT audit result were used in this study.

Results: 26/26 participating centres completed the questionnaire. After joining the trial, the number of centres routinely using tumour bed clips to guide whole-breast RT rose from 5 (19%) to 21 (81%). 20/26 (77%) centres now contour target volumes and organs at risk (OARs) in some or all patients compared with 14 (54%) before the trial. 14/26 (54%) centres offer inverse-planned IMRT for selected non-trial patients with breast cancer, and 10/14 (71%) have adopted the IMPORT HIGH trial protocol for target volume and OARs dose constraints. Only 2/26 (8%) centres used clip information routinely for breast treatment verification prior to IMPORT HIGH, a minority that has since risen to 7/26 (27%). Data on 1386 patients was included from the RCR audit. This suggested that more cases from IMPORT HIGH centres had surgical clips implanted (83 vs 67%), were treated using CT guided planning with full three-dimensional dose compensation (100 vs 75%), and were treated with photon boost RT (30 vs 8%).

Conclusion: The study suggests that participation in the IMPORT HIGH trial has played an important part in providing the guidance and support networks needed for the safe integration of advanced RT techniques, where appropriate, as a standard of care for breast cancer patients treated at participating cancer centres.

Advances in knowledge: We investigated the impact of the IMPORT HIGH trial on the adoption of advanced breast RT techniques in the UK and the trial has influenced non-trial breast RT techniques in terms of volume delineation, dosimetry, treatment delivery and verification.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
IMPORT HIGH trial schema.
Figure 2.
Figure 2.
Change in percentages of IMPORT centres using implanted markers to guide whole-breast radiotherapy planning for non-trial patients with breast cancer pre- and post-joining trial (n = 26).
Figure 3.
Figure 3.
Change in percentages of IMPORT centres performing target volumes and organs at risk delineations on non-trial patients with breast cancer pre- and post-joining trial (n = 26).
Figure 4.
Figure 4.
Change in percentages of IMPORT centres using intensity-modulated radiotherapy (IMRT) for non-trial patients with breast cancer pre- and post-joining trial (n = 14).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Miles E, Venables K. Radiotherapy quality assurance: facilitation of radiotherapy research and implementation of technology. Clin Oncol (R Coll Radiol) 2012; 24: 710–12. doi: 10.1016/j.clon.2012.06.006 - DOI - PubMed
    1. Venables K, Tsang Y, Ciurlionis L, Coles CE, Yarnold JR. Does participation in clinical trials influence the implementation of new techniques? A look at changing techniques in breast radiotherapy in the UK. Clin Oncol (R Coll Radiol) 2012; 24: e100–5. doi: 10.1016/j.clon.2012.06.010 - DOI - PubMed
    1. Coles C, Yarnold J; IMPORT Trials Management Group. The IMPORT trials are launched (September 2006). Clin Oncol (R Coll Radiol) 2006; 18: 587–90. doi: 10.1016/j.clon.2006.07.010 - DOI - PubMed
    1. Coles C, Yarnold J. Localising the tumour bed in breast radiotherapy. Clin Oncol (R Coll Radiol) 2010; 22: 36–8. doi: 10.1016/j.clon.2009.08.014 - DOI - PubMed
    1. Coles CE, Wilson CB, Cumming J, Benson JR, Forouhi P, Wilkinson JS, et al. . Titanium clip placement to allow accurate tumour bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial Management Group. Eur J Surg Oncol 2009; 35: 578–82. doi: 10.1016/j.ejso.2008.09.005 - DOI - PubMed

Publication types

MeSH terms